Journal of Clinical and Medical Images

Research Article

ISSN: 2640-9615 | Volume 7

Gum-Based Nano and Microparticles in Cancer Therapy

Akram M[1], Laila U[1], Iftikhar M[1], Riaz T[1], Rangasamy S[2], Garcia-Sierra F[3], Hasibuzzaman ML[4], Ozdemir FA[5], Sołowski G[5], Fitria N[6], Altable M[7], Hassan MM[8] and Parmar P[9]

[1]Department of Eastern Medicine, Government College University Faisalabad, Pakistan

[2]Department of Community Medicine, Sri Venkateshwaraa Medical College Hospital & Research Centre, India

[3]Department of Cell Biology, Center of Research and Advanced Studies of the National Polytechnical Institute, Mexico

[4]Department of Nutrition and Food Science, University of Dhaka, Bangladesh

[5]Department of Molecular Biology and Genetics, Faculty of Science and Art, Bingol University, Türkiye

[6]Department of Pharmacology and Clinical Pharmacy, Universitas Andalas, Indonesia

[7]Department of Neurology, Neuroceuta, (Virgen de Africa Clinic), Spain

[8]2Department of Biology, College of Science, Taif University, Saudi Arabia

[9]Additional Professor and HOD, Forensic Medicine and Toxicology, AIIMS, India

***Corresponding author:**

Muhammad Akram,
Department of Eastern Medicine, Government College University Faisalabad, Pakistan

Received: 06 Apr 2024
Accepted: 16 May 2024
Published: 22 May 2024
J Short Name: JCMI

Keywords:

Cancer therapy formulation; Nanocomposite; Anti-cancerous agent; Nanotechnology advantage

Citation:

Akram M, Gum-Based Nano and Microparticles in Cancer Therapy. J Clin Med Img. 2024; V7(15): 1-4

1. Abstract

In cancer therapy, the main challenging aspect for scientists is the delivery of safe and effective anti-cancerous agents. Usually, for normal cells, anti-cancerous agents possess toxic effects and show less bio-availability and stability. Many improvements have seen with recent developments in nano-technology, which shows an efficient and safe system for the delivery of anticancerous agents. So, the functional and physio-chemical characteristics of NPs (nano-particles) for every cancer agent are vary which includes photodynamic agents, inhibitors, chemotherapeutics, and many more. DDs are a critical systems that show therapeutic effects. Usually, the effectiveness of this system increases when natural material aids in this system, then it becomes non-immunogenic, non-toxic, bio-degradable &, and bio-compatible.

2. Introduction

Despite the development in treatment &investigating procedure still cancer is 2nd common illness in the united states on the report of cancer American society. From the research it was investigated that in the year 2017, almost 1.6 million cancer cases reported [1]. The management of cancer relay on the size, stage of tumor & biomarkers. First line treatment for cancer patient is chemo-therapy [2]. Chemotherapy effective because of their cytotoxic effects for cancerous cells. The role of immune-therapy & targeted therapy significant in the cure of cancer. The advantages of drug delivery are more as compared to conventional chemo-therapy. By using DDS, it not only delivers the medicine to tumor site but also facilitate the clearance of drug from immune & circulatory system, shows changes in physio-chemical characteristics of medicine, minimize the need of dose & manage the medicine release [3,4]. Number of ingredients like protein, lipid, polymers & metallic component employed as carriers of drug delivery for the encapsulation of several therapeutic component. They are classified into synthetic or natural material. Those components which are less expensive & widely present called natural material. Usually these are non-immunogenic, non-toxic, bio-degradable, bio-compatible. On material components functional group present which shows modification for conjugation with ligands & drug molecules to form the co-polymers [5]. Furthermore, they carry special binding sites protein

& other signal related to bio-chemical which help in delivery & tissue engineering. The role of these material in drug delivery system is very effective but also shows some disadvantages [6].

3. Nano-Composite & Synthetic Polymers

In the inhibition of cancerous cells role of di-chloride metallocene IV b & polyesters are very effective. They represent anti-cancerous medicine for new groups [7]. In cancerous therapy case amphiphilic duel shows significant response [8,9]. With the passage of time the importance of nano-technology increased because of their good diagnostic & cure effects against cancerous cells [10].

4. Liposomal Chemo-Therapeutic Formulation for Cancer Therapy

Table 1.

Table 1:

Name of brand	Active agent of drug	Composition of liposome	Target cancer	Manufacturer; Location & Country
Xomedauno	Dauno-rubicin	Cholesterol distearoyl-phosphatidylchloine	Related to acquired immune deficiency syndrome	NeXtar
myocet	Doxo-rubicin	Cholesterol endothelial progenitor cell	breast	B.V pharma teva
lipodox	Doxo-rubicin	Cholesterol PEG & HSPC	Breast, ovarian, acquired immune deficiency syndrome, multiple myeloma & sarcoma kaposis	Pharmaceutical sun
doxil	Doxo-rubicin	Cholesterol PEG & HSPC	Breast, ovarian, acquired immune deficiency syndrome &kaposis sarcoma	Laboratories of ben enue
Nano-platin or lipo-platin	Cisplatin	Cholesterol & choline soy phosphatidyl	Lungs & pancreatic	Inc& regulon
marqibo	Vincristine	Cholesterol &sphingo-myelin	Philadelphia -ve chromosome &lympho-blasticleukemia	Therapeutics & talon
onivyde	irinotecan	distearoyl-phosphatidylchloine& MPEG	Adeno-carcinoma & pancreatic	Pharmaceutical &merrimack
mepact	mi-famurtide	distearoyl-phosphatidylchloine& POPC	Osteo-sarcoma	Pharmaceutical &takeda

5. Anti-Cancer Therapeutics & Nps (Nano-Particles) Based Delivery Agent

Some anti-cancerous agent like photodynamic, chemo-therapeutic, nucleic agent & inhibitor of small molecule mostly requires efficient & safe DDs which enhance the stability, reduced the fast bio-clearance, high accumulation seen in the site of tumor & increased the potential of systemic administration. Further, MPs based DDS reduced the exposure of medicine respecting to body normal tissues.

6. Chemo-Therapeutic Drugs

Role of chemotherapy is significant against cancerous cells from a century. Number of anti-tumor agents are available which reduced & inhibit the growth of tumor [11]. Different chemo-therapeutic agents include alkaloids of plant, alkylating agents, anti-metabolites & anti-tumor anti-biotics. Some of these agents shows their specificity against some cancer, while other used in the management of different cancer. The example of this like in case of hydrophilic drug includes compounds of platinum, doxo-rubicin, gefitinib, curcumin, camptothecin, paclitaxel, fluorouracil 5 &epirubicin used for the cure of different cancerous cells. Most of these agents target the division of cells & then inhibit the growth cells through inhibiting the synthesis of DNA, function of protein & microtubule inhibits functions [12]. Taking medicine directly causes hazardous effects on the healthy tissues [13]. So, for the patient recovery from toxicity chemo-therapy is required. So, now a days the focus of researcher to enhance the DDS to the targeted area. The achievement of DDs comes after monitoring the level of drug and dose.

7. Small Molecules Inhibitors

These are organic component with present with different structure & their ranges of molecular weight varies from 500- 900 da, these small inhibitors diffuse from the cell easily & reach to intra-cellular site [14]. When these inhibitors come across the cell then it causes alteration in other molecules like protein & kills the cancerous cells [15]. They are classified into artificial, secondary metabolites, natural like anti-viral medicine. These agents show resemblance with chemo-therapy medicine, but they act as ribonucleic acid to knock-down the special protein. These agents also used to study several aspects related to biology like mitosis, control of cell cycle, expression of gene, oncogenic signal pathway, autophagy & apoptosis [16]. These agents used alone or in combination with NPs to cute the cancerous cells. This inhibitor possesses lots of advantage as compared to other molecules [17,18]. Usually, the intake of these inhibitors occurs through orally while other required parenteral or injections [19].

8. Nucleic Acid Therapeutic Agent

For the cure of cancerous cells target the genes expression & regulation is good approach. To obtain the whole knock-down of target

gene to reduce the down-stream network of protein 7 genes to minimize the chances of disease. The initial step which taken from this to control the gene knock-down involved anti-sense procedure, oligonucleotides chimeric & ribozymes [20]. In the cure of cancer, role of ribonucleic acid technology is significant because it produces various strategies of gene therapy.

9. Current Clinical Trials with Several siRNA Delivery Platform

Table 2

10. Advantages of Nano-Technology Based on DDS in the Therapy Of Cancer

Table 3

Table 2:

Title	Recruitment	Conditions	Interventions	Gender	Phase	Delivery
Those cancer which are not removed by surgery used APN401 to target these metastatic cancerous cells	Active	At different stages recurrent tumor present	Si-ribonucleic acid biological	all	Phase one	Si-ribonucleic acid transfection
In solid cancerous tumor study of CALAA-01	Terminated	Solid tumor of cancer	CALAA-01 medicine	all	Phase one	Nano-particles polymer
In advanced solid cancerous cells atu027 study	completed	Advanced solid tumor	Atu027 medicine	all	Phase one	Nano-particles in liquid
In case of lymphoma, myeloma & solid tumor DCRMYC study	Active	Solid tumor	DCR-MYC medicine	all	Phase one	Nano-particles of lipid
In case of secondary or primary cancer of liver 080301TKM	completed	With hepatic metastases cancerous cells	TKM drug	all	Phase one	Nano-particles of lipid
Gene targeting epha2	recruiting	Cancer advanced	DOPC, EphA2, si-ribonucleic acid	all	Phase one	Nano-particles of lipid
Immune-therapy of melanoma with si-ribonucleic acid	completed	Absence of central nervous system metastases & melanoma	Si-ribonucleic acida	all	Phase one	transfection
Pancreatic cancer metastasis & atu027 plus	completed	Ductal pancreatic & carcinoma	Gemcitabine & atu027 medicine	all	Phase one & two	Nano-particles of lipid
Cancer of hepatic cells in DCR-MYC	Active	Carcinoma of hepatic cells	DCR-MYC medicine	all	Phase one & two	

Table 3:

Features	Example
Controlled drug release	At the illness site the release of drug can be controlled, when specific signals come like special enzyme, ph., temperature, ultrasound [21,22].
Active target	Through selective recognition procedure includes antigen-antibody recognition & receptor of ligand & other modification ligands like mannose, folate & galactose [23,24,25].
Passive target	Due to increase retention & permeability effects it allows the carrier drug to store into the body interstitial tissues. The only conjugated drug store into the tumor tissues while the other diffuse out easily [26].
Protective effects	In a polymeric system the conjugation of drugs shows protective effects from in-activation & help their activity to accumulate for long period [27].
Solubilization effects	Micelles which are self-assembled with hydro-phobic core act as nano-container for enhancing the hydro-phobic medicine solubility [28,29].

11. Conclusion

Delivery of safe and effective anti-cancerous agents is big challenge in cancer therapy. Recent development in nano-technology shows efficient and safe system for the delivery of anticancerous agents. Functional and physio-chemical characteristics of nano-particles for every cancer agent is vary which includes photodynamic agent, inhibitors, chemotherapeutics etc. Effectiveness increases when natural material aid in system then it became non-immunogenic, non-toxic, bio-degradable and bio-compatible.

References

1. Cancer Facts & Figures. American Chemical Society. 2017.
2. Younes RN, Pereira JR, Fares AL, Gross JL. Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer. Rev Assoc Med Bras (1992). 2011; 57(6): 686-91.
3. Hossen S, Hossain MK, Basher MK, Mia MNH, Rahman MT, Uddin MJ. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J. Adv. Res. 2018; 15: 1-18.

4. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nano. 2007; 2: 751-60.
5. Ulbrich K, Hola K, Subr V, Bakandritsos A, Tucek J, Zboril R. Targeted drug delivery with polymers and magnetic nanoparticles: Covalent and noncovalent approaches, release control, and clinical studies. Chem. Rev. 2016; 116: 5338-431.
6. Ige OO, Umoru LE, Aribo S. Natural products: A minefield of biomaterials. ISRN Mater. Sci. 2012; 2012: 983062.
7. Carraher CE, Roner MR, Campbell AG, Moric-Johnson A, Miller L, Slawek P, et al. Group IVB metallocene polyesters containing camphoric acid and preliminary cancer cellactivity. Int. J. Polym. Mater. Polym. Biomater. 2018; 67: 469-79.
8. Zou H, Liu H. Synthesis of thermal and photo dual-responsive amphiphilic random copolymer via atom transfer radical polymerization and its control release of doxorubicin. Int. J. Polym. Mater. Polym. Biomater. 2017; 66: 955-62.
9. Massoumi B, Poorgholy N, Jaymand M. Multistimuli responsive polymeric nanosystems for theranostic applications. Int. J. Polym. Mater. Polym. Biomater. 2017; 66: 38-47.
10. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, et al. Effective use of nanocarriers as drug delivery system for the treatment of selected tumors. Int. J. Nanomed. 2017; 12: 7291-309.
11. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991; 83(11): 757-66.
12. Palchaudhuri R, Hergenrother PJ. DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. CurrOpinBiotechnol. 2007; 18(6): 497-503.
13. Celikoğlu SI, Karayel T, Demirci S, Celikoğlu F, Cağatay T. Direct injection of anti-cancer drugs into endobronchialtumours for palliation of major airway obstruction. Postgrad Med J. 1997; 73(857): 159-62.
14. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45(12): 2615-23.
15. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004; 3(4): 301-17.
16. Weiss WA, Taylor SS, Shokat KM. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol. 2007; 3(12): 739-44.
17. Gowda R, Jones NR, Banerjee S, Robertson GP. Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J NanomedNanotechnol. 2013; 4(6).
18. Madani SY, Naderi N, Dissanayake O, Tan A, Seifalian AM. A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int J Nanomedicine. 2011; 6: 2963-79.
19. Perumal V, Banerjee S, Das S, Sen RK, Mandal M. Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model. Cancer Nanotechnol. 2011; 2(1-6): 67-79.
20. Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012; 226(2): 365-79.
21. Husseini GA, Rapoport NY, Christensen DA, Pruitt JD, Pitt WG. Kinetics of ultrasonic release of doxorubicin from pluronic P105 micelles. Colloids and Surfaces B. 2002; 24(3-4): 253-64.
22. Rapoport N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery, Progress in Polymer Science. 2007; 32(8-9): 962-90.
23. Mikhail AS, Allen C. Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels. Journal of Controlled Release. 2009; 138(3): 214-23.
24. Betting DJ, Mu XY, Kafi K, McDonnel D, Rosas F, Gold DP, et al. Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells. Vaccine. 2009; 27(2): 250-9.
25. Gabano E, Ravera M, Cassino C, Bonetti S, Palmisano G, Osella D. Stepwise assembly of platinum—folic acid conjugates. Inorganica-ChimicaActa. 2008; 361(5): 1447-55.
26. Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends in Biotechnology. 2008; 26(10): 552-8.
27. Ko YT, Kale A, Hartner WC, PapahadjopoulosSternberg B, Torchilin VP. Self-assembling micellelike nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery. Journal of Controlled Release. 2009; 133(2): 132-8.
28. Liu B, Yang M, Li R, Ding Y, Qian X, Yu L, et al. The antitumor effect of novel docetaxel-loaded thermosensitive micelles," European Journal of Pharmaceutics and Biopharmaceutics. 2008; 69(2): 527-34.
29. Qiao W, Wang B, Wang Y, Yang L, Zhang Y, Shao P. Cancer Therapy Based on Nanomaterials and Nanocarrier Systems. 2010.